18 well-known pharmaceutical company executives change in half a month involving 4 chairman

Article source: Medical Rubik's Cube Info

Author: Sunshine

In a blink of an eye, November is already halfway through
.
Following the inventory of executive changes at the beginning of last month, another 18 companies experienced personnel changes in only half a month

Executives from foreign companies moved to local pharmaceutical companies, several chief financial officers and chief commercial officers resigned, and the (vice) chairman changed.
.
.
Under the development of the industry and the promotion of policies, the flow of talent in the pharmaceutical industry seems to have become the norm
.

Li Jinhui was transferred to the General Manager of the Emergency Department of Pfizer Hospital

On November 1, Ms.
Li Jinhui, the current general manager of the oncology and rare diseases business, was appointed as the general manager of the hospital's emergency department and reported to the president of China, Mr.
Peng Zhenke.
The work location is Beijing
.
Li Jinhui will immediately handover work and design the next level of organizational structure to ensure that the new structure of each department is officially effective on December 1

Li Jinhui joined Pfizer in 1998 and has been responsible for Pfizer China's product lines in many major disease areas, including sales management in areas such as anti-infection, cardiovascular, pain, oncology and rare diseases
.

Du Haochen, Vice President of AstraZeneca China, resigns and joins BeiGene

On November 1, Du Haochen, vice president of AstraZeneca China and head of the county business department, resigned
.
He is the fifth executive to leave AstraZeneca in the past two months

Recently, Wu Xiaobin, President of BeiGene, announced to employees that from November 18, 2021, Haochen Du will formally serve as the head of BeiGene's broad market, based in Shanghai
.

WOO SWEE LIAN, chairman of Ruizhi Pharmaceutical, resigns

On November 1, Ruizhi Pharmaceutical issued an announcement stating that Mr.
WOO SWEE LIAN had applied to resign from the company's chairman, director, and chairman of the board's strategy committee due to personal reasons, and continued to serve as the company's strategic consultant after resignation
.

Long Jiang served as the chief financial officer of Tianjing Biotechnology, and Zhu Jielun served as the chief strategy officer

On November 1, Tianjing Biotechnology announced two senior executive appointments, namely, Longjiang as the company’s chief financial officer and joining the company’s board of directors.
He is fully responsible for the company’s capital market business, investor relations, and company financial management.
Report to the company's founder and chairman Dr.
Zang Jingwu; Zhu Jielun was transferred to the company's chief strategy officer, focusing on planning and advancing corporate development strategies, major company strategic projects (including global cooperation, strategic investment and potential mergers and acquisitions), and early-stage venture capital
.

Zhang Su, Chief Financial Officer of Ascent Pharmaceuticals, resigns

On November 1, Yasheng Pharmaceutical issued an announcement stating that Zhang Su “wants to devote more time and energy to other businesses” to apply for resignation as chief financial officer
.

WuXi Biologics Chief Financial Officer Lu Shaohua resigns and Tu Ming takes over

On November 1, WuXi Biologics issued an announcement stating that Lu Shaohua retired and resigned as the company's chief financial officer to devote more time to his personal affairs
.
Tu Ming took over as the chief financial officer of WuXi Biologics and will be responsible for overseeing financial strategy, performance, reporting and business planning, as well as operational support such as funding, taxation, accounting management, and auditing

Zhou Song, vice president of Sinopharm, resigns

On November 1, Sinopharm announced that Mr.
Zhou Song had resigned from the company’s vice president and all other positions due to job changes
.

Zhou Rongwei, head of the internal audit and supervision department of Kangzhi Pharmaceutical, resigns and Li Rui takes over

On November 1, Kangzhi Pharmaceutical issued an announcement stating that Mr.
Zhou Rongwei had applied for resignation as the head of the company's internal audit and supervision department due to personal reasons.
After resignation, he will not hold any position in the company
.
Li Rui took over and was responsible for the company's internal audit and supervision

Zheng Zhiyong, Director and Deputy General Manager (Vice President) of Kingstone Asia Pharmaceuticals, resigns

On November 1, Kingstone Asia Pharmaceuticals issued an announcement stating that Mr.
Zheng Zhiyong had applied for the resignation of the company's deputy general manager (vice president) due to personal reasons.
After his resignation, he would still serve as a director of the company's fourth board of directors and a member of the nomination committee of the board of directors
.

Han Jing serves as Chief Commercial Officer of Corning Jerry

On November 2, Corning Jerry issued an announcement stating that Han Jing has been appointed as the chief commercial officer, who is mainly responsible for the company's commercialization and promotion, and will directly report to the chairman and president Dr.
Xu Ting
.

Han Jing graduated from Shanghai Second Medical University majoring in clinical medicine.
He has served as Boehringer Ingelheim Regional Manager, AstraZeneca Regional Sales Director, Bayer Regional Sales Director, Roche Pharmaceuticals BUO2 Senior Sales Director, Junshi Biologics Deputy General Manager, Jiahe Senior Vice President of Biology and other positions
.

Chief Commercial Officer Qian Wei resigns and Li Cong becomes the company's co-CEO

On November 3, Junshi Biotech announced that Chief Commercial Officer Qian Wei applied for resignation due to personal development reasons.
The last working day is November 12, 2021
.

Executive Director Li Cong will be appointed as the co-CEO, in charge of sales.
Li Cong has served as the sales director of Novo Nordisk's Shanghai office, Tonghua Dongbao East China region manager, marketing director, assistant general manager and general manager
.

Shen Weiyi serves as Vice Chairman of Stellite

On November 4, Stellite issued an announcement stating that because the former chairman of the company, Mr.
Hu Jinsheng, resigned on September 15, 2021, Mr.
Hu Jian served as the company’s new chairman, and his vice chairman was automatically removed from the position, so he elected Mr.
Shen Weiyi is the new vice chairman
.

Shen Weiyi joined Stellite in September 2009 and has served as project manager, deputy minister, minister of the Pharmaceutical and Chemical Department, and vice president of the research institute.
He is currently the director of the company and the president of the research institute
.

Wang Yangzhou served as CEO of Proton Bio

On November 8, Boten Biotech announced that it had appointed Dr.
Wang Yangzhou as the company's chief executive officer to be fully responsible for the operation and management of Boten Biotech and accelerate the construction of an end-to-end gene and cell therapy CDMO platform
.

Dr.
Yangzhou Wang graduated from the Department of Cellular and Molecular Biology, State University of New York.
He has more than 20 years of experience in international biotechnology, drug R&D service company operation management, business market development, and capital market M&A financing
.

Fosun Pharma's non-executive directors Gong Ping and Zhang Houlin resign

On November 9, Fosun Pharma issued an announcement stating that due to adjustments in work arrangements, Mr.
Gong Ping and Mr.
Zhang Houlin requested to resign as non-executive directors, and Mr.
Gong Ping also requested to resign as members of the Audit Committee of the Board of Directors
.

Zhou Song, Chief Financial Officer of Hengrui Pharmaceuticals, resigns

On November 12, Hengrui issued an announcement stating that Mr.
Zhou Song had applied for resignation from the company's chief financial officer due to personal reasons
.
After resigning the above-mentioned position, Mr.

Yao Jianlin, vice chairman of Wuzhong Medicine, resigns

On November 12, Wu Chinese Medicine announced that Mr.
Yao Jianlin had applied for resignation from the company’s vice chairman and director due to his reaching retirement age, and at the same time resigned as a member of the company’s board of directors’ corporate development and strategic investment committee
.

Ye Fang, Secretary of the Board of Directors of Wantai Biotechnology, resigns

On November 12, Wantai Biotechnology issued an announcement stating that Ms.
Ye Fang had applied for resignation as secretary of the company's board of directors due to personal career planning reasons
.
During the vacancy of the board secretary, Chairman Qiu Zixin performed the duties of the board secretary

Xu Ziying, Chairman of First Pharmaceutical, resigns

On November 13, First Pharmaceutical issued an announcement stating that Ms.
Xu Ziying had applied for the resignation of the company's 9th Board of Directors, Director, Chairman of the Strategy Committee and member of the Remuneration and Appraisal Committee due to work reasons
.
After resignation, he no longer holds any position in the company